combining a parp and pd-l1 inhibitor to treat prostate cancer
Published 6 years ago • 342 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:35
can vaccines and immune checkpoint inhibitors work together to treat prostate cancer?
-
0:57
when is the optimal time to use parp inhibitors in prostate cancer patients?
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
1:25
parp inhibitors: their applications and efficacy against prostate cancer
-
3:21
predicting pd-1 checkpoint inhibitor sensitivity in prostate cancer: potential molecular biomarkers
-
4:32
kidney cancer: combining parp inhibitors and immunotherapy
-
1:31
tackling disease progression whilst using parp inhibitors for prostate cancer
-
3:13
impact of specific mutations on parp inhibition in prostate cancer
-
4:06
the promise of parp inhibitors and their emerging role in ovarian cancer
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
1:53
parp inhibitors: game-changers for ovarian cancer patients?
-
6:25
combinations with parp inhibitors for ovarian cancer
-
38:47
parp inhibitors and their evolving role for the treatment of prostate cancer
-
21:21
role of immunotherapy and parp inhibitors
-
1:34
investigating the treatment of unselected mcrpc patients with a cdk 4/6 inhibitor plus abemaciclib
-
4:12
parp inhibitors
-
1:25
dr. emens on the combination of checkpoint inhibitors and parp inhibitors in ovarian cancer
-
1:43
parp inhibitors for prostate cancer